Objectives. To investigate the patterns of recurrence associated with superficial inguinal lymphadenectomy (SupIL) and vulvectomy for patients with Stage Ⅰ/Ⅱ vulvar cancer. Methods. A retrospective chart review iden...Objectives. To investigate the patterns of recurrence associated with superficial inguinal lymphadenectomy (SupIL) and vulvectomy for patients with Stage Ⅰ/Ⅱ vulvar cancer. Methods. A retrospective chart review identified patients from 1990-2001 with Stage Ⅰ/Ⅱ vulvar cancer that underwent SupIL and vulvectomy. Survival was analyzed using the Kaplan-Meier method with Fisher Exact and Chi-square tests for comparisons between groups. Results. 65 patients with Stage Ⅰ/Ⅱ vulvar cancer with a pathologically negative SupIL were identified (30 Stage Ⅰ, 35 Stage Ⅱ ). Three patients recurred in the inguinal region, (4.6% ) and 11 patients (16.9% ) recurred on the vulva. Two of the 11 patients died of disease, six patients are alive without evidence of disease after additional therapy. Five-year disease-free survival and overall survival were 66% and 97% , respectively. Risk of recurrence was not associated with smoking status, stage, or margin status. Conclusions. SupIL and vulvectomy for Stage Ⅰ /Ⅱ vulvar cancer have a low recurrence rate in the inguinal region when nodes are negative. The local recurrence rate (17% ) is acceptable, and overall survival is good using this conservative approach.展开更多
文摘Objectives. To investigate the patterns of recurrence associated with superficial inguinal lymphadenectomy (SupIL) and vulvectomy for patients with Stage Ⅰ/Ⅱ vulvar cancer. Methods. A retrospective chart review identified patients from 1990-2001 with Stage Ⅰ/Ⅱ vulvar cancer that underwent SupIL and vulvectomy. Survival was analyzed using the Kaplan-Meier method with Fisher Exact and Chi-square tests for comparisons between groups. Results. 65 patients with Stage Ⅰ/Ⅱ vulvar cancer with a pathologically negative SupIL were identified (30 Stage Ⅰ, 35 Stage Ⅱ ). Three patients recurred in the inguinal region, (4.6% ) and 11 patients (16.9% ) recurred on the vulva. Two of the 11 patients died of disease, six patients are alive without evidence of disease after additional therapy. Five-year disease-free survival and overall survival were 66% and 97% , respectively. Risk of recurrence was not associated with smoking status, stage, or margin status. Conclusions. SupIL and vulvectomy for Stage Ⅰ /Ⅱ vulvar cancer have a low recurrence rate in the inguinal region when nodes are negative. The local recurrence rate (17% ) is acceptable, and overall survival is good using this conservative approach.
